|
|
| | 1,2:3,4-DIBENZANTHRACENE Basic information |
| Product Name: | 1,2:3,4-DIBENZANTHRACENE | | Synonyms: | 94652, Dibenz[a,c]anthracene (purity);1,2,3,4-DIBENZANTHRACENE 97%;Dibenz[a,c]anthracene solution;1,2,3,4-Dibenzanthracene,97%;1.2:3.4-Dibenzanthracene 10mg [215-58-7];Dibenz[a,c]anthracene,1,2:3,4-Dibenzanthracene;1,2,3,4-Dibenzanthracene, 97% 100MG;1,2,3,4-1,2,3,4-Dibenzanthracene | | CAS: | 215-58-7 | | MF: | C22H14 | | MW: | 278.35 | | EINECS: | 205-920-8 | | Product Categories: | Aromatic Hydrocarbons (substituted) & Derivatives | | Mol File: | 215-58-7.mol |  |
| | 1,2:3,4-DIBENZANTHRACENE Chemical Properties |
| Melting point | 205-207 °C(lit.) | | Boiling point | 518 °C(lit.) | | density | 1.1489 (estimate) | | refractive index | 1.8120 (estimate) | | Fp | -18 °C | | storage temp. | Sealed in dry,2-8°C | | solubility | Chloroform (Slightly), Ethyl Acetate (Slightly), DMSO (Slightly) | | color | Clear plates, leaflets or needles from EtOH orAcOH | | Water Solubility | 1.6ug/L(25 ºC) | | BRN | 1912415 | | CAS DataBase Reference | 215-58-7(CAS DataBase Reference) | | IARC | 3 (Vol. Sup 7, 92) 2010 | | EPA Substance Registry System | Dibenz[a,c]anthracene (215-58-7) |
| | 1,2:3,4-DIBENZANTHRACENE Usage And Synthesis |
| Chemical Properties | LIGHT YELLOW TO BROWN POWDER | | Uses | Dibenzo[a,c]anthracene is a polycyclic aromatic hydrocarbon which are known carcinogens and environmental pollutants. | | Definition | ChEBI: Dibenz[a,c]anthracene is a carbopolycyclic compound. | | Safety Profile | Questionable carcinogen withexperimental tumorigenic data. Human mutation datareported. When heated to decomposition it emits acridsmoke and irritating fumes. | | Carcinogenicity | Dibenz[a,c]anthracene was
administered dermally to mice, either per se or as part of
initiation–promotion protocols. The working group concluded
that there was limited evidence for animal carcinogenicity.
In later studies on an initiation–promotion study on
mouse skin, low initiating doses gave negative results
when administered subcutaneously to mice, and tumor incidence
was not significantly increased over that observed in
controls when the compound was administered intraperitoneally
to newborn mice. |
| | 1,2:3,4-DIBENZANTHRACENE Preparation Products And Raw materials |
|